Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

123.88 +2.25 (+1.85%)

Streaming Delayed Price Updated: 2:41 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 02, 2023

Via ACCESSWIRE

Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

November 01, 2023

Via ACCESSWIRE

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

November 01, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

October 30, 2023

Via ACCESSWIRE

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

October 09, 2023

Via ACCESSWIRE

Protagonist Therapeutics Reports Granting of Inducement Award

October 03, 2023

Via ACCESSWIRE

What 6 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

September 25, 2023

Via Benzinga

Protagonist Receives $34 Million from Warrant Exercises

August 09, 2023

Via ACCESSWIRE

Expert Ratings for Protagonist Therapeutics ↗

July 06, 2023

Via Benzinga

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

September 22, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...

Via FinancialNewsMedia

Protagonist Therapeutics to Present at Upcoming Investor Conferences

September 05, 2023

Via ACCESSWIRE

Protagonist Therapeutics Reports Granting of Inducement Award

August 16, 2023

Via ACCESSWIRE

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 03, 2023

Via ACCESSWIRE

Where Protagonist Therapeutics Stands With Analysts ↗

June 12, 2023

Via Benzinga

Chart Of The Day: Protagonist Therapeutics - Wide Opinions ↗

June 09, 2023

Via Talk Markets

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter ↗

July 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Protagonist Therapeutics Reports Granting of Inducement Award

July 18, 2023

Via ACCESSWIRE

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

July 13, 2023

We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.

Via InvestorPlace

Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive ↗

July 06, 2023

JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,

Via Benzinga

Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

July 06, 2023

Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...

Via Benzinga

Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment ↗

July 05, 2023

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 04, 2023

Via Benzinga

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

July 04, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 03, 2023

Via Benzinga

Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 03, 2023

Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share.

Via Benzinga

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday ↗

July 03, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...

Via Benzinga

US Stocks Mixed; Dow Falls Over 50 Points ↗

July 03, 2023

U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%...

Via Benzinga

Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

June 28, 2023

With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.

Via MarketBeat

Topics Initial Public Offering

Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of

June 09, 2023

Via ACCESSWIRE

Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress

June 06, 2023

Via ACCESSWIRE

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.